A mutant fragment of PLP peptide
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

[Leu144, Arg147]-PLP (139-151) (trifluoroacetate salt)

Item No. 36895

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-histidyl-L-seryl-L-leucylglycyl-L-lysyl-L-leucyl-L-leucylglycyl-L-arginyl-L-prolyl-L-α-aspartyl-L-lysyl-L-phenylalanine, trifluoroacetate salt
Synonyms
  • H-His-Ser-Leu-Gly-Lys-Leu-Leu-Gly-Arg-Pro-Asp-Lys-Phe-OH
  • [Leu144, Arg147] Proteolipid Peptide (139-151)
Molecular Formula
C67H110N20O17 • XCF3COOH
Formula Weight
1467.7
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Peptide Sequence
HSLGKLLGRPDKF-OH
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMSO: 10 mg/mlEthanol: 2 mg/mlPBS (pH 7.2): 10 mg/ml
SMILES
OC([C@H](CC1=CC=CC=C1)NC([C@H](CCCCN)NC([C@H](CC(O)=O)NC([C@H]2N(CCC2)C([C@H](CCCNC(N)=N)NC(CNC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC(CNC([C@H](CC(C)C)NC([C@H](CO)NC([C@@H](N)CC3=CN=CN3)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C67H110N20O17.C2HF3O2/c1-37(2)26-46(81-61(98)48(28-39(5)6)83-59(96)43(18-10-12-22-68)78-53(89)33-75-58(95)47(27-38(3)4)82-63(100)51(35-88)86-56(93)42(70)30-41-32-73-36-77-41)57(94)76-34-54(90)79-45(20-14-24-74-67(71)72)65(102)87-25-15-21-52(87)64(101)84-49(31-55(91)92)62(99)80-44(19-11-13-23-69)60(97)85-50(66(103)104)29-40-16-8-7-9-17-40;3-2(4,5)1(6)7/h7-9,16-17,32,36-39,42-52,88H,10-15,18-31,33-35,68-70H2,1-6H3,(H,73,77)(H,75,95)(H,76,94)(H,78,89)(H,79,90)(H,80,99)(H,81,98)(H,82,100)(H,83,96)(H,84,101)(H,85,97)(H,86,93)(H,91,92)(H,103,104)(H4,71,72,74);(H,6,7)/t42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-;/m0./s1
InChi Key
IWSFVKVYISMJDW-FLOSWVKGSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $39

    Add

    5 mg

    $173

    Add

    10 mg

    $306

    Add

    25 mg

    $668

    Add
    Product Description

    [Leu144,Arg147]-PLP (139-151) is a mutant peptide fragment of myelin proteolipid protein (PLP) containing tryptophan-to-leucine and histidine-to-arginine substitutions at positions 144 and 147, respectively.1 Immunization with [Leu144, Arg147]-PLP (139-151) (50 µg) emulsified in complete Freund’s adjuvant (CFA) increases spleen levels of IL-4 in mice. It inhibits Th1 cell activation in vitro but not in vivo, where it induces the generation of regulatory T cells.2 Preimmunization with [Leu144, Arg147]-PLP (139-151) delays the onset of experimental autoimmune encephalomyelitis (EAE) induced by the encephalitogenic peptides PLP (178-191), myelin oligodendrocyte protein (MOG) (92-106), or myelin basic protein (MBP) in mice.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Katsara, M., Deraos, S., Tselios, T.V., et al. Immune responses of linear and cyclic PLP139-151 mutant peptides in SJL/J mice: Peptides in their free state versus mannan conjugation. Immunotherapy 6(6), 709-724 (2014).

    2. Nicholson, L.B., Murtaza, A., Hafler, B.P., et al. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc. Natl. Acad. Sci. USA 94(17), 9279-9284 (1997).